Mixed results for BMS’ Opdivo, Yervoy combo in kidney cancer
A combination of Bristol-Myers Squibb’s Opdivo and Yervoy has failed to significantly improve progression-free survival (PFS) compared to Pfizer’s Sutent in patients with renal cancer.
Read More
